CR20120526A - Proceso para la preparación de 4-{4[({[4-cloro-3-(trifluorometilo)-fenilo] amino} carbonilo) amino]-3-fluorofenoxi}-n-metilpiridino-2-carboxamida, sus sales y monohidrato - Google Patents

Proceso para la preparación de 4-{4[({[4-cloro-3-(trifluorometilo)-fenilo] amino} carbonilo) amino]-3-fluorofenoxi}-n-metilpiridino-2-carboxamida, sus sales y monohidrato

Info

Publication number
CR20120526A
CR20120526A CR20120526A CR20120526A CR20120526A CR 20120526 A CR20120526 A CR 20120526A CR 20120526 A CR20120526 A CR 20120526A CR 20120526 A CR20120526 A CR 20120526A CR 20120526 A CR20120526 A CR 20120526A
Authority
CR
Costa Rica
Prior art keywords
amino
fluorophenoxy
carboxamide
carbonyl
salts
Prior art date
Application number
CR20120526A
Other languages
English (en)
Inventor
Juergen Stiehl
Werner Heilmann
Michael Logers
Joachim Rehse
Michael Gottfried
Saskia Wichmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120526(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CR20120526A publication Critical patent/CR20120526A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Containers And Plastic Fillers For Packaging (AREA)

Abstract

La presente invención se refiere a un procedimiento para la preparación de 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-N-metilpiridina-2-carboxamida, sus sales y su monohidrato
CR20120526A 2010-04-15 2012-10-16 Proceso para la preparación de 4-{4[({[4-cloro-3-(trifluorometilo)-fenilo] amino} carbonilo) amino]-3-fluorofenoxi}-n-metilpiridino-2-carboxamida, sus sales y monohidrato CR20120526A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15

Publications (1)

Publication Number Publication Date
CR20120526A true CR20120526A (es) 2013-03-11

Family

ID=44070712

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120526A CR20120526A (es) 2010-04-15 2012-10-16 Proceso para la preparación de 4-{4[({[4-cloro-3-(trifluorometilo)-fenilo] amino} carbonilo) amino]-3-fluorofenoxi}-n-metilpiridino-2-carboxamida, sus sales y monohidrato

Country Status (39)

Country Link
US (5) US8748622B2 (es)
EP (1) EP2558448B1 (es)
JP (1) JP5934182B2 (es)
KR (2) KR20170129276A (es)
CN (2) CN102947271B (es)
AR (2) AR081060A1 (es)
AU (1) AU2011240113B2 (es)
BR (1) BR112012026117B1 (es)
CA (1) CA2796238C (es)
CL (1) CL2012002840A1 (es)
CO (1) CO6630136A2 (es)
CR (1) CR20120526A (es)
CU (2) CU24123B1 (es)
DK (1) DK2558448T3 (es)
DO (2) DOP2012000268A (es)
EC (1) ECSP12012234A (es)
ES (1) ES2542610T3 (es)
GT (1) GT201200280A (es)
HK (1) HK1200831A1 (es)
HR (1) HRP20150885T1 (es)
HU (1) HUE026821T2 (es)
IL (2) IL222348B (es)
JO (1) JO3158B1 (es)
MA (1) MA34156B1 (es)
MX (1) MX2012011734A (es)
MY (2) MY162359A (es)
NZ (1) NZ602997A (es)
PE (2) PE20160838A1 (es)
PL (1) PL2558448T3 (es)
PT (1) PT2558448E (es)
RS (1) RS54219B1 (es)
RU (1) RU2581585C2 (es)
SG (2) SG184172A1 (es)
SI (1) SI2558448T1 (es)
TN (1) TN2012000492A1 (es)
TW (2) TWI475992B (es)
UA (1) UA110613C2 (es)
UY (2) UY33290A (es)
WO (1) WO2011128261A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877933B2 (en) * 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
UA93673C2 (ru) 2005-03-07 2011-03-10 Баер Шеринг Фарма Акциенгезельшафт Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
MY183969A (en) 2012-09-25 2021-03-17 Bayer Pharma AG Combination of regorafenib and acetylsalicylic acid for treating cancer
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
WO2015049698A2 (en) * 2013-10-04 2015-04-09 Hetero Research Foundation Process for regorafenib
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
WO2016005874A1 (en) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
CA3011662A1 (en) * 2016-01-18 2017-07-27 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
AU2018276273B2 (en) 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1769795B1 (en) 2001-12-03 2013-07-24 Bayer HealthCare LLC Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
AU2003209118A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
CA2526636C (en) 2003-05-20 2012-10-02 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
US20060078617A1 (en) 2004-08-27 2006-04-13 Fritz Schueckler Pharmaceutical compositions for the treatment of cancer
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
ES2532377T3 (es) 2004-09-29 2015-03-26 Bayer Healthcare Llc Procedimiento de preparación de 4-{4-[({[4-[cloro-3-(trifluorometil)fenil]amino}carbonil) amino]fenoxi}N-metilpiridina-2-carboxamida
US8877933B2 (en) 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
UA93673C2 (ru) 2005-03-07 2011-03-10 Баер Шеринг Фарма Акциенгезельшафт Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
WO2007053573A2 (en) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
EP1957069A2 (en) 2005-11-14 2008-08-20 Bayer Healthcare, LLC Treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010509253A (ja) * 2006-11-09 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉｉ
CA2669158A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
DE602007012589D1 (de) 2006-12-20 2011-03-31 Bayer Healthcare Llc 4-ä4-Ä(ä3-TERT-BUTYL-1-Ä3-(HYDROXYMETHYL)-PHENYLÜ-1H-PYRAZOL-5-YLü-CARBAMOYL)-AMINOÜ-3-FLUOROPHENOXYü -N-METHYLPYRIDIN-2-CARBOXAMID SOWIE PRODRUGS UND
EP2114403A2 (en) 2007-01-19 2009-11-11 Bayer Healthcare, LLC Treatment of cancers having resistance to chemotherapeutic agents
JP5885012B2 (ja) 2007-01-19 2016-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CA2741087A1 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
MX2011012201A (es) 2009-05-15 2011-12-08 Novartis Ag Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico.
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MX2013003695A (es) 2010-10-01 2013-05-20 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
PE20141031A1 (es) 2011-06-28 2014-08-21 Bayer Healthcare Llc Composicion farmaceutica oftalmologica topica que contiene regorafenib
US20140235678A1 (en) 2011-06-28 2014-08-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
JO3479B1 (ar) 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب

Also Published As

Publication number Publication date
IL253119B (en) 2018-03-29
SG184172A1 (en) 2012-11-29
IL222348A0 (en) 2012-12-31
TN2012000492A1 (en) 2014-04-01
RU2581585C2 (ru) 2016-04-20
US10822305B2 (en) 2020-11-03
ES2542610T3 (es) 2015-08-07
US20190144391A1 (en) 2019-05-16
US20170334857A1 (en) 2017-11-23
MX2012011734A (es) 2012-12-17
UY33290A (es) 2011-12-01
US20170057918A1 (en) 2017-03-02
ECSP12012234A (es) 2012-11-30
TWI539951B (zh) 2016-07-01
CU24123B1 (es) 2015-08-27
TWI475992B (zh) 2015-03-11
PL2558448T3 (pl) 2015-10-30
RU2012148386A (ru) 2014-05-20
IL253119A0 (en) 2017-08-31
GT201200280A (es) 2014-07-23
HUE026821T2 (en) 2016-07-28
SG10201501221UA (en) 2015-04-29
US8748622B2 (en) 2014-06-10
DK2558448T3 (en) 2015-08-24
IL222348B (en) 2018-08-30
JP5934182B2 (ja) 2016-06-15
KR20130061670A (ko) 2013-06-11
PE20130181A1 (es) 2013-02-23
CN102947271A (zh) 2013-02-27
CU20120147A7 (es) 2013-01-30
JP2013523851A (ja) 2013-06-17
BR112012026117B1 (pt) 2022-08-30
US9458107B2 (en) 2016-10-04
HK1200831A1 (en) 2015-08-14
UA110613C2 (uk) 2016-01-25
NZ602997A (en) 2014-10-31
CO6630136A2 (es) 2013-03-01
JO3158B1 (ar) 2017-09-20
BR112012026117A2 (pt) 2015-09-08
HRP20150885T1 (hr) 2015-10-09
US20130116442A1 (en) 2013-05-09
MY162359A (en) 2017-06-15
KR20170129276A (ko) 2017-11-24
KR101800041B1 (ko) 2017-11-21
MY177066A (en) 2020-09-03
RS54219B1 (en) 2015-12-31
CU20140060A7 (es) 2014-10-02
AR116395A2 (es) 2021-05-05
AU2011240113A1 (en) 2012-10-11
DOP2012000268A (es) 2012-12-15
WO2011128261A1 (en) 2011-10-20
TW201204356A (en) 2012-02-01
PT2558448E (pt) 2015-09-01
CN102947271B (zh) 2016-11-09
DOP2016000285A (es) 2016-11-30
AR081060A1 (es) 2012-06-06
EP2558448B1 (en) 2015-05-20
PE20160838A1 (es) 2016-09-24
CA2796238C (en) 2019-12-31
BR112012026117A8 (pt) 2017-12-19
CA2796238A1 (en) 2011-10-20
UY39590A (es) 2022-01-31
SI2558448T1 (sl) 2015-11-30
AU2011240113B2 (en) 2014-12-18
EP2558448A1 (en) 2013-02-20
MA34156B1 (fr) 2013-04-03
TW201509415A (zh) 2015-03-16
US20140221661A1 (en) 2014-08-07
CN103980191A (zh) 2014-08-13
CL2012002840A1 (es) 2013-01-18

Similar Documents

Publication Publication Date Title
CR20120526A (es) Proceso para la preparación de 4-{4[({[4-cloro-3-(trifluorometilo)-fenilo] amino} carbonilo) amino]-3-fluorofenoxi}-n-metilpiridino-2-carboxamida, sus sales y monohidrato
CO7111315A2 (es) Dihidrato de un compuesto de benzotiofeno o de una de sus sales y proceso para su producción
CU20070069A7 (es) Proceso para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
CO7010843A2 (es) Métodos para la producción de 4 amino 3 cloro 6 (4 cloro 2 fluor 3 metoxifenil) piridin 2 carboxilato de metilo
BR112012020629A2 (pt) forma cristalina, e, método para a terapia de um distúrbio
EA201200123A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
CR20120467A (es) Procedimiento para la preparación de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1, 2, 3, 4-tetrahidroisoquinolin-7-sulfonamida
EA201100230A1 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
UY33879A (es) Proceso para la preparación de amidas del ácido pirazol carboxílico
CY1115682T1 (el) Νεα μεθοδος συνθεσης ιβαβραδινης και των αλατων προσθηκης της με ενα φαρμακευτικως αποδεκτο οξυ
UA118008C2 (uk) Спосіб синтезу (2е)-3-(3,4-диметоксифеніл)проп-2-еннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
UA117900C2 (uk) Спосіб синтезу 3-(2-бром-4,5-диметоксифеніл)пропаннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
EA201201571A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
EA201300281A2 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
EA201301020A1 (ru) Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MD20160072A2 (ro) Procedeu nou de sinteză a 7-metoxi-naftalină-1-carbaldehidei şi aplicarea acesteia în sinteza agomelatinei
CR20130300A (es) Nuevo procedimiento de síntesis de la agomelatina